Dr. Abeliuk received his Ph.D. studying how bacterial cells divide using high-throughput genetic and molecular biology techniques. His work has been published by multiple international journals and holds patent US9150916. While at Stanford, he started, built and sold KissMe LLC and also founded Classroom.tv, Inc. KissMe was an application that hit a million users within the first few weeks and was acquired in 2009. Prior coming to Stanford, Eduardo was at SMaL Camera Tech., an MIT startup acquired by Cypress Semi. He also interned at Motorola, Synopsys and Lightspeed Venture Partners. Eduardo holds a Ph.D. in Electrical Engineering from Stanford University.
Dr. Hillson is a world-recognized expert in the field of biological computer-aided design and manufacture, with over 8 years experience leading teams of software engineers, laboratory automation engineers, and biological experimentalists towards the collaborative development and operational demonstration of synthetic biology infrastructure for biomanufacturing applications. He performed his postdoctoral fellowship in microbiology at Stanford, and holds a PhD in biophysics from Harvard.
Dr. Richardson is a Distinguished Postdoctoral Fellow in the Physical Biosciences Division at Lawrence Berkeley National Lab, working at the Joint BioEnergy Institute (JBEI) on massive scale synthetic biology projects in biogeochemistry and bioremediation. Sarah has developed state of the art tools for the rapid, automated design of multikilobase synthetic genes and the automated design of assemblable, modular, synthetic chromosomes. Sarah is the recipient of the Turock Award for Promising Young Scientists and the Jupur Dinesh Thekdi Award from Johns Hopkins University. Sara holds a Ph.D. in Human Genetics from the Johns Hopkins University.
Dr. Keith Wilson is the Founder and Chief Science Officer at Nalo Therapeutics. Previously, he was the Chief Science Officer at Oxford BioTherapeutics. Keith has led research efforts at PDL BioPharma through the corporate transition into Facet Biotech, Abbott Laboratories, Abbvie, and now Oxford. He has led internal scientific and business reviews of pipeline portfolio and strategy leading to corporate directional change and has been responsible for implementation of new pipeline strategies. He was a Postdoctoral Fellow at Stanford University and later the Director of Computational Biology and Genomics at EOS Biotechnology and PDL BioPharma. Dr. Wilson holds Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University.